Showing results 4 to 5 of 5
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology | 2021 | ||
2008 |